mTOR Inhibitors Market Analysis - Global Industry Size, Share, Trends and Forecast 2022 - 2030

CHAPTER 1. Industry Overview of mTOR Inhibitors Market

1.1. Definition and Scope

1.1.1. Definition of mTOR Inhibitors

1.1.2. Market Segmentation

1.1.3. Years Considered for the Study

1.1.4. Assumptions and Acronyms Used

1.1.4.1. Market Assumptions and Market Forecast

1.1.4.2. Acronyms Used in Global mTOR Inhibitors Market

1.2. Summary

1.2.1. Executive Summary 

1.2.2. mTOR Inhibitors Market By Product Type

1.2.3. mTOR Inhibitors Market By Indication

1.2.4. mTOR Inhibitors Market By Route of Administration

1.2.5. mTOR Inhibitors Market By End-Users

1.2.6. mTOR Inhibitors Market By Distribution Channel

1.2.7. mTOR Inhibitors Market By Region

CHAPTER 2. Research Approach

2.1. Methodology

2.1.1. Research Programs

2.1.2. Market Size Estimation

2.1.3. Market Breakdown and Data Triangulation

2.2. Data Source

2.2.1. Secondary Sources

2.2.2. Primary Sources

CHAPTER 3. Market Dynamics And Competition Analysis

3.1. Market Drivers

3.1.1. Driver 1

3.1.2. Driver 2

3.2. Restraints and Challenges

3.2.1. Restraint 1

3.2.2. Restraint 2

3.3. Growth Opportunities

3.3.1. Opportunity 1

3.3.2. Opportunity 2 

3.4. Porter’s Five Forces Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of Substitute

3.4.4. Threat of New Entrants

3.4.5. Degree of Competition

3.5. Market Concentration Ratio and Market Maturity Analysis of mTOR Inhibitors Market

3.5.1. Go To Market Strategy

3.5.1.1. Introduction

3.5.1.2. Growth

3.5.1.3. Maturity

3.5.1.4. Saturation

3.5.1.5. Possible Development

3.6. Technological Roadmap for mTOR Inhibitors Market

3.7. Value Chain Analysis

3.7.1. List of Key Manufacturers 

3.7.2. List of Customers

3.7.3. Level of Integration

3.8. Cost Structure Analysis

3.8.1. Price Trend of Key Raw Materials

3.8.2. Raw Material Suppliers

3.8.3. Proportion of Manufacturing Cost Structure

3.8.3.1. Raw Material

3.8.3.2. Labor Cost

3.8.3.3. Manufacturing Expense

3.9. Regulatory Compliance

3.10. Competitive Landscape, 2021

3.10.1. Player Positioning Analysis

3.10.2. Key Strategies Adopted By Leading Players

CHAPTER 4. mTOR Inhibitors Market By Product Type

4.1. Introduction

4.2. mTOR InhibitorsRevenueBy Product Type

4.2.1. mTOR Inhibitors Revenue (US$ Mn) and Forecast, By Product Type, 2018-2030

4.2.2. Rapamune

4.2.2.1. Rapamune Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

4.2.3. Afinitor

4.2.3.1. Afinitor Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

4.2.4. Torisel

4.2.4.1. Torisel Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

4.2.5. Zortress

4.2.5.1. Zortress Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

4.2.6. Others

4.2.6.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

CHAPTER 5. mTOR Inhibitors Market By Indication

5.1. Introduction

5.2. mTOR Inhibitors Revenue (US$ Mn) By Indication

5.2.1. mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

5.2.2. Oncology

5.2.2.1. Oncology Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

5.2.3. Immunosuppressant

5.2.3.1. Immunosuppressant Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

5.2.4. Organ Transplantation

5.2.4.1. Organ Transplantation Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

5.2.5. Others

5.2.5.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

CHAPTER 6. mTOR Inhibitors Market By Route of Administration

6.1. Introduction

6.2. mTOR Inhibitors Revenue (US$ Mn) By Route of Administration

6.2.1. mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

6.2.2. Oral

6.2.2.1. Oral Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

6.2.3. Intravenous

6.2.3.1. Intravenous Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

CHAPTER 7. mTOR Inhibitors Market By End-Users

7.1. Introduction

7.2. mTOR Inhibitors Revenue (US$ Mn) By End-Users

7.2.1. mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

7.2.2. Hospitals

7.2.2.1. Hospitals Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

7.2.3. Specialty Clinics

7.2.3.1. Specialty Clinics Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

7.2.4. Others

7.2.4.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

CHAPTER 8. mTOR Inhibitors Market By Distribution Channel

8.1. Introduction

8.2. mTOR Inhibitors Revenue (US$ Mn) By Distribution Channel

8.2.1. mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

8.2.2. Hospital Pharmacies

8.2.2.1. Hospital Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

8.2.3. Retail Pharmacies

8.2.3.1. Retail Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

8.2.4. Online Pharmacies

8.2.4.1. Online Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030

CHAPTER 9. North America mTOR Inhibitors Market By Country

9.1. North America mTOR InhibitorsOverview

9.2. U.S.

9.2.1. U.S. mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

9.2.2. U.S. mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

9.2.3. U.S. mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

9.2.4. U.S. mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

9.2.5. U.S. mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

9.3. Canada

9.3.1. Canada mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

9.3.2. Canada mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

9.3.3. Canada mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

9.3.4. Canada mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

9.3.5. Canada mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

9.4. North America PEST Analysis

CHAPTER 10. Europe mTOR Inhibitors Market By Country

10.1. Europe mTOR InhibitorsOverview

10.2. U.K.

10.2.1. U.K.mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

10.2.2. U.K.mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

10.2.3. U.K. mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

10.2.4. U.K.mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

10.2.5. U.K.mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

10.3. Germany

10.3.1. Germany mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

10.3.2. Germany mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

10.3.3. Germany mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

10.3.4. Germany mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

10.3.5. Germany mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

10.4. France

10.4.1. France mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

10.4.2. France mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

10.4.3. France mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

10.4.4. France mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

10.4.5. France mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

10.5. Spain

10.5.1. Spain mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

10.5.2. Spain mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

10.5.3. Spain mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

10.5.4. Spain mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

10.5.5. Spain mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

10.6. Rest of Europe

10.6.1. Rest of Europe mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

10.6.2. Rest of Europe mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

10.6.3. Rest of Europe mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

10.6.4. Rest of Europe mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

10.6.5. Rest of Europe mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

10.7. Europe PEST Analysis

CHAPTER 11. Asia Pacific mTOR Inhibitors Market By Country

11.1. Asia Pacific mTOR InhibitorsOverview

11.2. China

11.2.1. China mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

11.2.2. China mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

11.2.3. China mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

11.2.4. China mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

11.2.5. China mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

11.3. Japan

11.3.1. Japan mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

11.3.2. Japan mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

11.3.3. Japan mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

11.3.4. Japan mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

11.3.5. Japan mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

11.4. India

11.4.1. India mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

11.4.2. India mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

11.4.3. India mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

11.4.4. India mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

11.4.5. India mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

11.5. Australia

11.5.1. Australia mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

11.5.2. Australia mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

11.5.3. Australia mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

11.5.4. Australia mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

11.5.5. Australia mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

11.6. South Korea

11.6.1. South Korea mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

11.6.2. South Korea mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

11.6.3. South Korea mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

11.6.4. South Korea mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

11.6.5. South Korea mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

11.7. Rest of Asia-Pacific

11.7.1. Rest of Asia-PacificmTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

11.7.2. Rest of Asia-Pacific mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

11.7.3. Rest of Asia-Pacific mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

11.7.4. Rest of Asia-Pacific mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

11.7.5. Rest of Asia-Pacific mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

11.8. Asia Pacific PEST Analysis

CHAPTER 12. Latin America mTOR Inhibitors Market By Country

12.1. Latin AmericamTOR InhibitorsOverview

12.2. Brazil

12.2.1. Brazil mTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

12.2.2. Brazil mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

12.2.3. Brazil mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

12.2.4. Brazil mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

12.2.5. Brazil mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

12.3. Mexico

12.3.1. MexicomTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

12.3.2. Mexico mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

12.3.3. Mexico mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

12.3.4. Mexico mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

12.3.5. Mexico mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

12.4. Rest of Latin America

12.4.1. Rest of Latin AmericamTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

12.4.2. Rest of Latin America mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

12.4.3. Rest of Latin America mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

12.4.4. Rest of Latin America mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

12.4.5. Rest of Latin America mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

12.5. Latin America PEST Analysis

CHAPTER 13. Middle East & Africa mTOR Inhibitors Market By Country 

13.1. Middle East & Africa mTOR InhibitorsOverview

13.2. GCC

13.2.1. GCCmTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

13.2.2. GCC mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

13.2.3. GCC mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

13.2.4. GCC mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

13.2.5. GCC mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

13.3. South Africa

13.3.1. South AfricamTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

13.3.2. South Africa mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

13.3.3. South Africa mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

13.3.4. South Africa mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

13.3.5. South Africa mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

13.4. Rest of Middle East & Africa

13.4.1. Rest of Middle East & AfricamTOR Inhibitors Revenue (US$ Mn) and Forecast By Product Type, 2018-2030

13.4.2. Rest of Middle East & Africa mTOR Inhibitors Revenue (US$ Mn) and Forecast By Indication, 2018-2030

13.4.3. Rest of Middle East & Africa mTOR Inhibitors Revenue (US$ Mn) and Forecast By Route of Administration, 2018-2030

13.4.4. Rest of Middle East & Africa mTOR Inhibitors Revenue (US$ Mn) and Forecast By End-Users, 2018-2030

13.4.5. Rest of Middle East & Africa mTOR Inhibitors Revenue (US$ Mn) and Forecast By Distribution Channel, 2018-2030

13.5. Middle East & Africa PEST Analysis

CHAPTER 14. Player Analysis Of mTOR Inhibitors Market

14.1. mTOR Inhibitors Market Company Share Analysis

14.2. Competition Matrix

14.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment

14.2.2. New Product Launches and Product Enhancements

14.2.3. Mergers And Acquisition InGlobal mTOR Inhibitors Market

14.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements

CHAPTER 15. Company Profile

15.1. AbbVie Inc.

15.1.1. Company Snapshot

15.1.2. Business Overview

15.1.3. Financial Overview

15.1.3.1. Revenue (US$ Mn), 2021

15.1.3.2. AbbVie Inc.2021 mTOR InhibitorsBusiness Regional Distribution

15.1.4. Product/Service and Specification

15.1.5. Recent Developments & Business Strategy

15.1.6. Hospitals Plant Footprint Analysis

15.2. Accord Healthcare

15.3. AstraZeneca

15.4. Bristol-Myers Squibb Company

15.5. Dr. Reddy’s Laboratories Ltd.

15.6. Eli Lilly and Company

15.7. Hikma Pharmaceuticals PLC

15.8. Merck & Co Inc.

15.9. Novartis AG

15.10. Pfizer Inc.

15.11. Teva Pharmaceuticals Industries Ltd.

15.12. Zydus Pharmaceuticals, Inc.